Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Michele Colicchia, Alessandro Morlacco, John C. Cheville & R. Jeffrey Karnes. (2017) Genomic tests to guide prostate cancer management following diagnosis. Expert Review of Molecular Diagnostics 17:4, pages 367-377.
Read now
Read now
Articles from other publishers (25)
Shuoming Zhou, Hongliang Fu, Changming Liu, Ziqiang Zhu, Jiabin Zhang, Wubin Weng, Jian Kang & Qiang Liu. (2021) Value of 11C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases. Frontiers in Oncology 10.
Crossref
Crossref
Alessandro Caputo, Antonio D’Antonio, Domenico Memoli, Francesco Sabbatino, Vincenzo Altieri & Pio Zeppa. (2021) Ki67 in Gleason Pattern 3 as a Marker of the Presence of Higher-Grade Prostate Cancer. Applied Immunohistochemistry & Molecular Morphology 29:2, pages 112-117.
Crossref
Crossref
Su Su Thae Hnit, Mu Yao, Chanlu Xie, Guangbo Ge, Ling Bi, Shenyi Jin, Lijing Jiao, Ling Xu, Lina Long, Hong Nie, Yu Jin, Linda Rogers, Natalka Suchowerska, Matthew Wong, Tao Liu, Paul De Souza, Zhong Li & Qihan Dong. (2020) Transcriptional regulation of G2/M regulatory proteins and perturbation of G2/M Cell cycle transition by a traditional Chinese medicine recipe. Journal of Ethnopharmacology 251, pages 112526.
Crossref
Crossref
Ling Bi, Chanlu Xie, Mu Yao, Su Su Thae Hnit, Soma Vignarajan, Yilun Wang, Qian Wang, Zhichao Xi, Hongxi Xu, Zhong Li, Paul Souza, Andrew Tee, Matthew Wong, Tao Liu, Xiaodong Zhao, Jia Zhou, Ling Xu & Qihan Dong. (2018)
The histone chaperone complex FACT promotes proliferative switch of G
0
cancer cells
. International Journal of Cancer 145:1, pages 164-178.
Crossref
Crossref
Charalampos Mamoulakis, Charalampos Mavridis, George Georgiadis, Charalampos Belantis, Ioannis E. Zisis, Iordanis Skamagkas, Ioannis Heretis, Wallace A. Hayes & Aristidis M. Tsatsakis. 2019. Biomarkers in Toxicology. Biomarkers in Toxicology
869
881
.
Marco Moschini, Martin Spahn, Agostino Mattei, John Cheville & R. Jeffrey Karnes. (2016) Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. BMC Medicine 14:1.
Crossref
Crossref
Z Xi, M Yao, Y Li, C Xie, J Holst, T Liu, S Cai, Y Lao, H Tan, H-X Xu & Q Dong. (2016) Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation. Cell Death & Disease 7:6, pages e2252-e2252.
Crossref
Crossref
Fausto Petrelli, Ivano Vavassori, Mary Cabiddu, Andrea Coinu, Mara Ghilardi, Karen Borgonovo, Veronica Lonati & Sandro Barni. (2016) Predictive Factors for Reclassification and Relapse in Prostate Cancer Eligible for Active Surveillance: A Systematic Review and Meta-analysis. Urology 91, pages 136-142.
Crossref
Crossref
Ghazaleh Ghobadi, Jeroen de Jong, Birgit G. Hollmann, Baukelien van Triest, Henk G. van der Poel, Conchita Vens & Uulke A. van der Heide. (2016) Histopathology-derived modeling of prostate cancer tumor control probability: Implications for the dose to the tumor and the gland. Radiotherapy and Oncology 119:1, pages 97-103.
Crossref
Crossref
Patrice Desmeules, Hélène Hovington, Molière Nguilé-Makao, Caroline Léger, André Caron, Louis Lacombe, Yves Fradet, Bernard Têtu & Vincent Fradet. (2015) Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy. Diagnostic Pathology 10:1.
Crossref
Crossref
Mu Yao, Chanlu Xie, Mei-Yee Kiang, Ying Teng, David Harman, Jessamy Tiffen, Qian Wang, Paul Sved, Shisan Bao, Paul Witting, Jeff Holst & Qihan Dong. (2015) Targeting of cytosolic phospholipase A2α impedes cell cycle re-entry of quiescent prostate cancer cells. Oncotarget 6:33, pages 34458-34474.
Crossref
Crossref
George Lee, Asha Singanamalli, Haibo Wang, Michael D. Feldman, Stephen R. Master, Natalie N. C. Shih, Elaine Spangler, Timothy Rebbeck, John E. Tomaszewski & Anant Madabhushi. (2015) Supervised Multi-View Canonical Correlation Analysis (sMVCCA): Integrating Histologic and Proteomic Features for Predicting Recurrent Prostate Cancer. IEEE Transactions on Medical Imaging 34:1, pages 284-297.
Crossref
Crossref
Rong Shi, Zhen Zhao, Hui Zhou, Min Wei, Wen-Li Ma, Jue-Yu Zhou & Wan-Long Tan. (2014) Reduced expression of PinX1 correlates to progressive features in patients with prostate cancer. Cancer Cell International 14:1.
Crossref
Crossref
S. Dijkstra, P.F.A. Mulders & J.A. Schalken. (2014) Clinical use of novel urine and blood based prostate cancer biomarkers: A review. Clinical Biochemistry 47:10-11, pages 889-896.
Crossref
Crossref
Yi Lu & Chikezie Madu. 2014. Biomarkers in Toxicology. Biomarkers in Toxicology
771
783
.
Tapan Bhavsar, Peter McCue & Ruth Birbe. (2013) Molecular Diagnosis of Prostate Cancer: Are We Up to Age?. Seminars in Oncology 40:3, pages 259-275.
Crossref
Crossref
Dragan Ilic, Molly M Neuberger, Mia Djulbegovic & Philipp Dahm. (2013) Screening for prostate cancer. Cochrane Database of Systematic Reviews 2013:1.
Crossref
Crossref
David Ian Quinn & Gregory P. Swanson. 2013. Biomarkers in Oncology. Biomarkers in Oncology
189
247
.
Antoun Toubaji, Siobhan Sutcliffe, Alcides Chaux, Kristen Lecksell, Jessica Hicks, Angelo M. De Marzo, Elizabeth A. Platz & George J. Netto. (2012) Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer: a tissue microarray and digital imaging analysis–based study of 428 cases. Human Pathology 43:11, pages 1852-1865.
Crossref
Crossref
MARKETA SZTALMACHOVA, MARIAN HLAVNA, JAROMIR GUMULEC, MONIKA HOLUBOVA, PETR BABULA, JAN BALVAN, JIRI SOCHOR, VERONIKA TANHAUSEROVA, MARTINA RAUDENSKA, SONA KRIZKOVA, VOJTECH ADAM, TOMAS ECKSCHLAGER, RENE KIZEK & MICHAL MASARIK. (2012) Effect of zinc(II) ions on the expression of pro- and anti-apoptotic factors in high-grade prostate carcinoma cells. Oncology Reports 28:3, pages 806-814.
Crossref
Crossref
Siebren Dijkstra, Agus Rizal A. H. Hamid, Gisèle H. J. M. Leyten & Jack A. Schalken. (2012) Personalized Management in Low-Risk Prostate Cancer: The Role of Biomarkers. Prostate Cancer 2012, pages 1-7.
Crossref
Crossref
Gregory P. Swanson & David Quinn. (2011) Using Molecular Markers to Help Predict Who Will Fail after Radical Prostatectomy. Prostate Cancer 2011, pages 1-15.
Crossref
Crossref
Jean-Marie Bruey, Hagop Kantarjian, Wanlong Ma, Zeev Estrov, Chenhsiung Yeh, Amber Donahue, Heather Sanders, Susan O’Brien, Michael Keating & Maher Albitar. (2010) Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leukemia Research 34:10, pages 1320-1324.
Crossref
Crossref
Jean-Marie Bruey, Hagop Kantarjian, Zeev Estrov, Zhong Zhang, Wanlong Ma, Ferras Albitar, Adam Abdool, Deborah Thomas, Chenhsiung Yeh, Susan O’Brien & Maher Albitar. (2010) Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia. Leukemia Research 34:2, pages 173-176.
Crossref
Crossref
Dragan Ilic, Denise O'Connor, Sally Green & Timothy J Wilt. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.